Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab
Short-term Results With Faricimab After Multiple Sequential Treatment Switches Due to Resistance With Both Aflibercept and Ranibizumab in Neovascular Age-related Macular Degeneration
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Glostrup, Denmark, 2600
- Miklos Schneider
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria
- Presence of neovascular age-related macular degeneration (AMD) in the study eye
- Previous treatment with minimum 6 consecutive, monthly aflibercept (Eylea®) injections in the study eye without optimal treatment response, defined as persisting intraretinal fluid or subretinal fluid or both on optical coherence tomography scans
- Subsequently, a sequential switch to ranibizumab (Lucentis®), with minimum 1 injection, also without optimal response
- Finally, a sequential treatment switch from ranibizumab to faricimab.
Exclusion criteria
- Neovascular conditions other than AMD (e.g., choroidal neovascularisation due to other causes) or co-existence of other retinal disease in the study eye
- Significant optical media opacities that would result in poor imaging quality on OCT scans in the study eye
- Intraocular surgery in the study eye 3 months before or within 1 month after the treatment switch
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients
Patients who received intravitreal faricimab injections between May and September, in 2023.
and conform the inclusion/exclusion criteria.
|
The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients responding to the treatment switch
Time Frame: 4 weeks
|
Defined as reduction or disappearance of the intra- or subretinal fluid at 4 weeks following a single injection of faricimab
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in patient characteristics between individuals responding and not responding to faricimab
Time Frame: 4 weeks
|
4 weeks
|
|
|
Changes in central retinal thickness after the treatment switch
Time Frame: 4 weeks
|
Measured on optical coherence tomography (OCT) scans
|
4 weeks
|
|
Changes in pigment epithelium detachment (PED) height after the treatment switch
Time Frame: 4 weeks
|
Measured on optical coherence tomography (OCT) scans
|
4 weeks
|
|
Changes in best-corrected visual acuity after the treatment switch
Time Frame: 4 weeks
|
4 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of ocular and systemic adverse events
Time Frame: 4 weeks
|
Safety endpoint
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Miklos Schneider, MD, PhD, Rigshospitalet Glostrup
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MULTISW-VAB1SHOT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.